ID   OAS3_RAT                Reviewed;        1137 AA.
AC   Q5MYT7;
DT   05-SEP-2012, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-2005, sequence version 1.
DT   27-MAR-2024, entry version 94.
DE   RecName: Full=2'-5'-oligoadenylate synthase 3;
DE            Short=(2-5')oligo(A) synthase 3;
DE            Short=2-5A synthase 3;
DE            EC=2.7.7.84;
GN   Name=Oas3;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Large intestine;
RX   PubMed=17024523; DOI=10.1007/s00239-006-0073-3;
RA   Perelygin A.A., Zharkikh A.A., Scherbik S.V., Brinton M.A.;
RT   "The mammalian 2'-5' oligoadenylate synthetase gene family: evidence for
RT   concerted evolution of paralogous Oas1 genes in Rodentia and
RT   Artiodactyla.";
RL   J. Mol. Evol. 63:562-576(2006).
CC   -!- FUNCTION: Interferon-induced, dsRNA-activated antiviral enzyme which
CC       plays a critical role in cellular innate antiviral response. In
CC       addition, it may also play a role in other cellular processes such as
CC       apoptosis, cell growth, differentiation and gene regulation.
CC       Synthesizes preferentially dimers of 2'-5'-oligoadenylates (2-5A) from
CC       ATP which then bind to the inactive monomeric form of ribonuclease L
CC       (RNase L) leading to its dimerization and subsequent activation.
CC       Activation of RNase L leads to degradation of cellular as well as viral
CC       RNA, resulting in the inhibition of protein synthesis, thus terminating
CC       viral replication. Can mediate the antiviral effect via the classical
CC       RNase L-dependent pathway or an alternative antiviral pathway
CC       independent of RNase L (By similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3 ATP = 5'-triphosphoadenylyl-(2'->5')-adenylyl-(2'->5')-
CC         adenosine + 2 diphosphate; Xref=Rhea:RHEA:34407, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:67143; EC=2.7.7.84;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000305};
CC   -!- ACTIVITY REGULATION: Produced as a latent enzyme which is activated by
CC       dsRNA generated during the course of viral infection. Strongly
CC       activated by long dsRNAs at least 50 nucleotides in length. ssRNA does
CC       not activate the enzyme. {ECO:0000250|UniProtKB:Q9Y6K5}.
CC   -!- SUBUNIT: Monomer. {ECO:0000250|UniProtKB:Q9Y6K5}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}.
CC   -!- DOMAIN: OAS domain 3 is catalytically active. OAS domain 1 has no
CC       catalytic activity but is essential for recognition of long dsRNAs.
CC       {ECO:0000250|UniProtKB:Q9Y6K5}.
CC   -!- SIMILARITY: Belongs to the 2-5A synthase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY250706; AAP76224.1; -; mRNA.
DR   RefSeq; NP_001009493.1; NM_001009493.1.
DR   AlphaFoldDB; Q5MYT7; -.
DR   SMR; Q5MYT7; -.
DR   STRING; 10116.ENSRNOP00000073069; -.
DR   PhosphoSitePlus; Q5MYT7; -.
DR   GeneID; 494202; -.
DR   KEGG; rno:494202; -.
DR   AGR; RGD:1359319; -.
DR   CTD; 4940; -.
DR   RGD; 1359319; Oas3.
DR   eggNOG; ENOG502S649; Eukaryota.
DR   InParanoid; Q5MYT7; -.
DR   OrthoDB; 4638494at2759; -.
DR   PhylomeDB; Q5MYT7; -.
DR   PRO; PR:Q5MYT7; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IBA:GO_Central.
DR   GO; GO:0001730; F:2'-5'-oligoadenylate synthetase activity; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0003725; F:double-stranded RNA binding; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0051607; P:defense response to virus; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0039530; P:MDA-5 signaling pathway; ISO:RGD.
DR   GO; GO:0071650; P:negative regulation of chemokine (C-C motif) ligand 5 production; ISO:RGD.
DR   GO; GO:2000342; P:negative regulation of chemokine (C-X-C motif) ligand 2 production; ISO:RGD.
DR   GO; GO:0035395; P:negative regulation of chemokine (C-X-C motif) ligand 9 production; ISO:RGD.
DR   GO; GO:0071659; P:negative regulation of IP-10 production; ISO:RGD.
DR   GO; GO:0060339; P:negative regulation of type I interferon-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; ISO:RGD.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; ISO:RGD.
DR   GO; GO:0071639; P:positive regulation of monocyte chemotactic protein-1 production; ISO:RGD.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; ISO:RGD.
DR   GO; GO:0009615; P:response to virus; ISS:UniProtKB.
DR   GO; GO:0039529; P:RIG-I signaling pathway; ISO:RGD.
DR   CDD; cd05400; NT_2-5OAS_ClassI-CCAase; 3.
DR   Gene3D; 1.10.1410.20; 2'-5'-oligoadenylate synthetase 1, domain 2; 3.
DR   Gene3D; 3.30.460.10; Beta Polymerase, domain 2; 3.
DR   InterPro; IPR018952; 2-5-oligoAdlate_synth_1_dom2/C.
DR   InterPro; IPR006117; 2-5OAS_C_CS.
DR   InterPro; IPR043518; 2-5OAS_N_CS.
DR   InterPro; IPR006116; NT_2-5OAS_ClassI-CCAase.
DR   InterPro; IPR043519; NT_sf.
DR   InterPro; IPR002934; Polymerase_NTP_transf_dom.
DR   PANTHER; PTHR11258:SF7; 2'-5'-OLIGOADENYLATE SYNTHASE-LIKE PROTEIN 2; 1.
DR   PANTHER; PTHR11258; 2-5 OLIGOADENYLATE SYNTHETASE; 1.
DR   Pfam; PF01909; NTP_transf_2; 1.
DR   Pfam; PF10421; OAS1_C; 3.
DR   SUPFAM; SSF81301; Nucleotidyltransferase; 3.
DR   SUPFAM; SSF81631; PAP/OAS1 substrate-binding domain; 3.
DR   PROSITE; PS00832; 25A_SYNTH_1; 1.
DR   PROSITE; PS00833; 25A_SYNTH_2; 2.
DR   PROSITE; PS50152; 25A_SYNTH_3; 3.
PE   2: Evidence at transcript level;
KW   Acetylation; Antiviral defense; ATP-binding; Cytoplasm; Immunity;
KW   Innate immunity; Magnesium; Metal-binding; Nucleotide-binding;
KW   Nucleotidyltransferase; Nucleus; Reference proteome; Repeat; RNA-binding;
KW   Transferase.
FT   CHAIN           1..1137
FT                   /note="2'-5'-oligoadenylate synthase 3"
FT                   /id="PRO_0000418631"
FT   REGION          6..341
FT                   /note="OAS domain 1"
FT                   /evidence="ECO:0000305"
FT   REGION          12..56
FT                   /note="Interaction with dsRNA"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K5"
FT   REGION          185..199
FT                   /note="Interaction with dsRNA"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K5"
FT   REGION          342..461
FT                   /note="Linker"
FT                   /evidence="ECO:0000305"
FT   REGION          434..462
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          462..792
FT                   /note="OAS domain 2"
FT                   /evidence="ECO:0000305"
FT   REGION          800..1134
FT                   /note="OAS domain 3"
FT                   /evidence="ECO:0000305"
FT   COMPBIAS        434..460
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         854
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P00973"
FT   BINDING         866
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:P00973"
FT   BINDING         868
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:P00973"
FT   BINDING         938
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:P00973"
FT   BINDING         997
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P29728"
FT   BINDING         1000
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P00973"
FT   BINDING         1019
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P00973"
FT   SITE            154
FT                   /note="Interaction with dsRNA"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K5"
FT   SITE            242
FT                   /note="Interaction with dsRNA"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K5"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y6K5"
SQ   SEQUENCE   1137 AA;  126205 MW;  B46A310B613485DF CRC64;
     MDLYHTPAGA LDKLVAHSLH PAPEFTAAVR RALGSLDNVL RKNGAGGLQR PRVIRIIKGG
     AHARGTALRG GTDVELVIFL DCLRSFGDQK TCHTEILGAI QALLESWGCN PGPGLTFEFS
     GPKASGILQF RLASVDQENW IDVSLVPAFD ALGQLHSEVK PTPNVYSSLL SSHCQAGEHS
     ACFTELRKNF VNIRPVKLKN LILLVKHWYR QVQTQVVRAT LPPSYALELL TIFAWEQGCR
     KDAFSLAQGL RTVLALIQRN KHLCIFWTEN YGFEDPAVGE FLRRQLKRPR PVILDPADPT
     WDLGNGTAWC WDVLAKEAEY SFNQQCFKEA SGALVQPWEG PGLPCAGILD LGHPIQQGAK
     HALEDNNGHL AVQPMKESLQ PSNPARGLPE TATKISAMPD PTVTETHKSL KKSVHPKTVS
     ETVVNPSSHV WITQSTASSN TPPGHSSMST AGSQMGPDLS QIPSKELDSF IQDHLRPSSQ
     FQQQVRQAID TILCCLREKC VDKVLRVSKG GSFGRGTDLR GKCDVELVIF YKTLGDFKGQ
     NSHQTEILCD MQAQLQRWCQ NPAPGLSLQF IEQKSNALHL QLVPTNLSNR VDLSVLPAFD
     AVGPLKSGAK PLPETYSSLL SSGCQAGEHA ACFAELRRNF INTRPAKLRS LMLLVKHWYR
     QVAARFEGGE TAGAALPPAY ALELLTVFAW EQGCGEQKFS MAEGLRTVLR LVQQHQSLCI
     YWTVNYSVQD PAIRAHLLRQ LRKARPLILD PADPTWNMDQ GNWKLLAQEA AALESQVCLQ
     SRDGNLVPPW DVMPALLHQT PAQNLDKFIC EFLQPDRHFL TQVKRAVDTI CSFLKENCFR
     NSTIKVLKVV KGGSSAKGTA LQGRSDADLV VFLSCFRQFS EQGSHRAEII AEIQAQLEAC
     QQKQRFDVKF EISKRKNPRV LSFTLTSKTL LGQSVDFDVL PAFDALGQLK SGSRPDPRVY
     TDLIQSYSNA GEFSTCFTEL QRDFISSRPT KLKSLIRLVK HWYQQCNKTV KGKGSLPPQH
     GLELLTVYAW ERGSQNPQFN MAEGFRTVLE LIGQYRQLCV YWTINYGAED ETIGDFLKMQ
     LQKPRPVILD PADPTGNLGH NARWDLLAKE AAAYTSALCC MDKDGNPIKP WPVKAAV
//
